Business
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics
Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nStrategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network\n\n\n\nPhysicians nationwide now have the ability to order Shield\n\n\n\nShield is proven to increase screening rates with a 93% screening adherence rate\n\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through the nationwide connectivity of Quest Diagnostics, equipping clinicians with access to blood-based screening innovation for colorectal cancer (CRC) through one of the largest diagnostic ecosystems in the United States.\n\n\nShield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal cancer in average-risk adults aged 45 and older. Under the agreement, providers that order lab testing from Quest can now directly access Shield through their existing Quest account and electronic health record (EHR).\n\n\nQuest provides healthcare connectivity solutions to nearly 650,000 clinician and hospital accounts annually in the United States. Providers can also utilize Quest’s approximately 2,000 patient service centers and approximately 6,000 in-office phlebotomists across the United States for blood draws for Shield.\n\n\n“Activating our strategic collaboration with Quest marks a pivotal milestone in broadening access to Shield and empowering primary care physicians across the country to bring the lifesaving advantages of early detection to their patients with just a blood draw,” said AmirAli Talasaz, Guardant Health co-CEO. “Shield’s innovative technology supported by Quest’s vast, nationwide infrastructure will strengthen our ability to fundamentally transform colorectal cancer screening by equipping doctors with a quick, easier screening option patients are far more likely to complete.”\n\n\nAs part of the strategic arrangement, Quest’s national commercial sales team will actively educate primary care physicians about access to the test.\n\n\nColorectal cancer is the second leading cause of cancer-related deaths in the U.S. with a 91 percent five-year survival rate if caught in early stages.1 Yet, over 54 million people do not complete the r...